Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Growth 2023-2029
Description
Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Growth 2023-2029
The global Group A and Group C Meningococcal Polysaccharide Vaccine market size is projected to grow from US$ 278.8 million in 2022 to US$ 422 million in 2029; it is expected to grow at a CAGR of 6.1% from 2023 to 2029.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.
LPI (LP Information)' newest research report, the “Group A and Group C Meningococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world Group A and Group C Meningococcal Polysaccharide Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Group A and Group C Meningococcal Polysaccharide Vaccine sales for 2023 through 2029. With Group A and Group C Meningococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Group A and Group C Meningococcal Polysaccharide Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Group A and Group C Meningococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Group A and Group C Meningococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Group A and Group C Meningococcal Polysaccharide Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Group A and Group C Meningococcal Polysaccharide Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Group A and Group C Meningococcal Polysaccharide Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Group A and Group C Meningococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Class 1 Vaccine
Class II Vaccine
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Walvax
Lanzhou Institute of Biological Products
AIM Bio
Sanofi Pasteur
GSK
Hualan Bio
ZFSW
Changsheng
Kanghua Bio
Key Questions Addressed in this Report
What is the 10-year outlook for the global Group A and Group C Meningococcal Polysaccharide Vaccine market?
What factors are driving Group A and Group C Meningococcal Polysaccharide Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Group A and Group C Meningococcal Polysaccharide Vaccine market opportunities vary by end market size?
How does Group A and Group C Meningococcal Polysaccharide Vaccine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
99 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Group A and Group C Meningococcal Polysaccharide Vaccine by Country/Region, 2018, 2022 & 2029
- 2.2 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Type
- 2.2.1 Class 1 Vaccine
- 2.2.2 Class II Vaccine
- 2.3 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
- 2.3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2018-2023)
- 2.3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Type (2018-2023)
- 2.4 Group A and Group C Meningococcal Polysaccharide Vaccine Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.5 Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
- 2.5.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Market Share by Application (2018-2023)
- 2.5.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Application (2018-2023)
- 3 Global Group A and Group C Meningococcal Polysaccharide Vaccine by Company
- 3.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Breakdown Data by Company
- 3.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Company (2018-2023)
- 3.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sales Market Share by Company (2018-2023)
- 3.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Company (2018-2023)
- 3.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Company (2018-2023)
- 3.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Revenue Market Share by Company (2018-2023)
- 3.3 Global Group A and Group C Meningococcal Polysaccharide Vaccine Sale Price by Company
- 3.4 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Group A and Group C Meningococcal Polysaccharide Vaccine Product Location Distribution
- 3.4.2 Players Group A and Group C Meningococcal Polysaccharide Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
- 4 World Historic Review for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region
- 4.1 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Geographic Region (2018-2023)
- 4.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Group A and Group C Meningococcal Polysaccharide Vaccine Market Size by Country/Region (2018-2023)
- 4.2.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Sales by Country/Region (2018-2023)
- 4.2.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
- 4.4 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
- 4.5 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
- 4.6 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales Growth
- 5 Americas
- 5.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country
- 5.1.1 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2023)
- 5.1.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2023)
- 5.2 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
- 5.3 Americas Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region
- 6.1.1 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Region (2018-2023)
- 6.1.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Region (2018-2023)
- 6.2 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
- 6.3 APAC Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
- 7 Europe
- 7.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine by Country
- 7.1.1 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2023)
- 7.1.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2023)
- 7.2 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
- 7.3 Europe Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine by Country
- 8.1.1 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Type
- 8.3 Middle East & Africa Group A and Group C Meningococcal Polysaccharide Vaccine Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
- 10.3 Manufacturing Process Analysis of Group A and Group C Meningococcal Polysaccharide Vaccine
- 10.4 Industry Chain Structure of Group A and Group C Meningococcal Polysaccharide Vaccine
- 11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Group A and Group C Meningococcal Polysaccharide Vaccine Distributors
- 11.3 Group A and Group C Meningococcal Polysaccharide Vaccine Customer
- 12 World Forecast Review for Group A and Group C Meningococcal Polysaccharide Vaccine by Geographic Region
- 12.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Size Forecast by Region
- 12.1.1 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Region (2024-2029)
- 12.1.2 Global Group A and Group C Meningococcal Polysaccharide Vaccine Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Type
- 12.7 Global Group A and Group C Meningococcal Polysaccharide Vaccine Forecast by Application
- 13 Key Players Analysis
- 13.1 Walvax
- 13.1.1 Walvax Company Information
- 13.1.2 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.1.3 Walvax Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.1.4 Walvax Main Business Overview
- 13.1.5 Walvax Latest Developments
- 13.2 Lanzhou Institute of Biological Products
- 13.2.1 Lanzhou Institute of Biological Products Company Information
- 13.2.2 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.2.3 Lanzhou Institute of Biological Products Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.2.4 Lanzhou Institute of Biological Products Main Business Overview
- 13.2.5 Lanzhou Institute of Biological Products Latest Developments
- 13.3 AIM Bio
- 13.3.1 AIM Bio Company Information
- 13.3.2 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.3.3 AIM Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 AIM Bio Main Business Overview
- 13.3.5 AIM Bio Latest Developments
- 13.4 Sanofi Pasteur
- 13.4.1 Sanofi Pasteur Company Information
- 13.4.2 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.4.3 Sanofi Pasteur Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Sanofi Pasteur Main Business Overview
- 13.4.5 Sanofi Pasteur Latest Developments
- 13.5 GSK
- 13.5.1 GSK Company Information
- 13.5.2 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.5.3 GSK Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.5.4 GSK Main Business Overview
- 13.5.5 GSK Latest Developments
- 13.6 Hualan Bio
- 13.6.1 Hualan Bio Company Information
- 13.6.2 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.6.3 Hualan Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.6.4 Hualan Bio Main Business Overview
- 13.6.5 Hualan Bio Latest Developments
- 13.7 ZFSW
- 13.7.1 ZFSW Company Information
- 13.7.2 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.7.3 ZFSW Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.7.4 ZFSW Main Business Overview
- 13.7.5 ZFSW Latest Developments
- 13.8 Changsheng
- 13.8.1 Changsheng Company Information
- 13.8.2 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.8.3 Changsheng Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.8.4 Changsheng Main Business Overview
- 13.8.5 Changsheng Latest Developments
- 13.9 Kanghua Bio
- 13.9.1 Kanghua Bio Company Information
- 13.9.2 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Product Portfolios and Specifications
- 13.9.3 Kanghua Bio Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.9.4 Kanghua Bio Main Business Overview
- 13.9.5 Kanghua Bio Latest Developments
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
